Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Azacitidine 11venetoclax 8decitabine and cedazuridine drug combination 6Tacrolimus 4Decitabine 4Cyclophosphamide 4fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Injections 3Cytarabine 3Busulfan 3Biopsy 3ruxolitinib 2itacitinib 2fludarabine 2Whole-Body Irradiation 2Vorinostat 2Specimen Handling 2Sirolimus 2Mycophenolic Acid 2Lenalidomide 2CPX-351 2veliparib 1tagraxofusp 1spartalizumab 1seclidemstat 1sabatolimab 1quizartinib 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelomonocytic, Chronic × guadecitabine × Clear all
NCT02935361 2026-01-29

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

University of Southern California

Phase 1/2 Active not recruiting
33 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡